Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies

Hinchcliff, Emily; Westin, Shannon N.; Molin, Graziela Dal; Lafargue, Christopher J.; Coleman, Robert L.

doi:10.1136/ijgc-2019-000499

Cited by 3 publications

(1 citation statement)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The additional use of DNA damaging agents might lead to an increased dependence on PARP1 activity for repair and by this would amplify a cells/tumors sensitivity to PARP inhibition. Combination therapies of PARPi with other DNA damaging therapies such as radiation therapy, chemotherapeutic drugs (e.g., Doxorubicin) [10] or anti-angiogenic therapy and immunotherapy are being assessed to improve cytotoxicity, and by this, the therapy efficacy and outcome as discussed in a recent review [11].…”

Section: Introductionmentioning

confidence: 99%

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes

Sankaranarayanan

Kossatz

Weber

et al. 2020

JCM

View full text Add to dashboard Cite

The central paradigm of novel therapeutic approaches in cancer therapy is identifying and targeting molecular biomarkers. One such target is the nuclear DNA repair enzyme Poly-(ADP ribose) polymerase 1 (PARP1). Sensitivity to PARP inhibition in certain cancers such as gBRCAmut breast and ovarian cancers has led to its exploitation as a target. The overexpression of PARP1 in several types of cancer further evoked interest in its use as an imaging target. While PARP1-targeted inhibitors have fast developed and approved in this past decade, determination of PARP1 expression might help to predict the response to PARP inhibitor treatment. This has the potential of improving prognosis and moving towards tailored therapy options and/or dosages. This review summarizes the recent pre-clinical advancements in imaging and theranostic PARP1 targeted tracers. To assess PARP1 levels, several imaging probes with fluorescent or beta/gamma emitting radionuclides have been proposed and three have advanced to ongoing clinical evaluation. Apart from its diagnostic value in detection of primary tumors as well as metastases, this shall also help in delivering therapeutic radionuclides to PARP1 overexpressing tumors. Henceforth nuclear medicine has now advanced towards conjugating theranostic radionuclides to PARP1 inhibitors. This paves the way for a future of PARP1-targeted theranostics and personalized therapy.

show abstract

Section: Introductionmentioning

confidence: 99%